News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Conference News ACC 2024 Another Beta-blocker Blow: REDUCE-AMI Confirms No Benefit After Acute MI Michael O'Riordan April 07, 2024
News Conference News ACC 2023 STREAM-2: Half-Dose Tenecteplase Safe, Effective in Older STEMI Patients L.A. McKeown March 10, 2023
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2022 Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms Todd Neale April 02, 2022
News Conference News ACC 2021 Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions L.A. McKeown May 21, 2021
News Conference News ACC 2021 High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE Michael O'Riordan May 15, 2021
News Conference News ACC 2020 Ischemia Burden Not Linked to Angina in Nonobstructive CAD: CIAO Michael O'Riordan March 31, 2020
News Conference News ACC 2020 PRONOMOS: Rivaroxaban Beats Enoxaparin for Preventing VTE After Orthopedic Surgery Yael L. Maxwell March 31, 2020
Presentation ACC 2020 The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes Presenter: Deepal L. Bhatt March 30, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Conference News ACC 2019 New Primary Prevention Guidelines Axe Aspirin, Pushing Routine Check-ins, Social Clues Instead Michael O'Riordan March 17, 2019
News Conference News ACC 2019 ACC 2019: A Smartwatch, Low-risk TAVR, and Bempedoic Acid Are Hoping for Luck Saint Paddy’s Day Weekend Shelley Wood March 11, 2019
News Conference News ACC 2018 Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial Caitlin E. Cox March 14, 2018
News Conference News ACC 2018 ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit Michael O'Riordan March 10, 2018
Presentation ACC 2017 EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Presenter: Jeff Weitz March 20, 2017
News Conference News ACC 2017 VISION: High-Sensitivity Troponin Strongly Linked to Increased Death From Myocardial Injury After Noncardiac Surgery L.A. McKeown March 19, 2017
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017